GlaucoPharm is the developer of TG-46, a topical treatment for glaucoma. TG-46 is useful for the treatment of diseases modulated by the pyrimidinergic receptor P2Y6. The P2Y6 receptor has been identified in trabecular meshwork (TM) cells, an area of tissue in the eye that is responsible for draining the aqueous humor.
The companys product shows evidence of a novel mechanism of action, making it a potential alternative to first-line drugs. It binds tightly and selectively to P2Y6R and reduces intraocular pressure by up to 45%, compared to the 25% to 35% reduction produced by most drugs on the market.
TG-46 is highly stable chemically and enzymatically, with a duration of action longer than 3.5 hours. Its synthesis is facile and results in good yields, and preliminary data show that it causes fewer side effects than most standard treatments.